Moderna Stock Tanks on Review Arguing Covid Vaccine Booster Might Not Be Needed – Barrons

Text size

A person holds a vial of Moderna Covid-19 vaccine


Fred Tanneau/AFP via Getty Images


Moderna

stock, as well as shares of Covid vaccine makers

BioNTech

and

Novavax,

were sliding after an article in the Lancet suggested that a booster shot wouldn’t be necessary for most people.

In morning trading, Moderna (MRNA) stock has dropped 5.8%, while BioNTech (BNTX) had fallen 5.6%, and Novavax (NVAX) has declined 2.4%.

Pfizer

(PFE), BioNTech’s partner, had slipped 2%. The

S&P 500

was up 0.1%.

The Lancet article was a review of data from clinical trials, as well as efficacy in the real world. The authors, who included the FDA’s Marion Gruber and Philip Krause, argue that there is no evidence that the vaccines lose their ability to protect against “severe disease, even when there appear to be declines over time in vaccine efficacy against symptomatic disease.”

The debate over whether to use booster shots in the U.S. is ongoing, even as Israel begins to discuss the possibility of a fourth shot. Continued vaccinations would produce longer-term revenue streams for vaccine makers.

Write to Ben Levisohn at ben.levisohn@barrons.com

Leave a Reply

Your email address will not be published. Required fields are marked *